Compass Therapeutics (CMPX) – Investment Analysts’ Recent Ratings Changes

Compass Therapeutics (NASDAQ: CMPX) has recently received a number of price target changes and ratings updates:

• 3/24/2026 – Compass Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $12.00 price target on the stock.
• 3/12/2026 – Compass Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 3/5/2026 – Compass Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $9.00 price target on the stock.
• 3/5/2026 – Compass Therapeutics had its “outperform” rating reaffirmed by William Blair.
• 3/5/2026 – Compass Therapeutics had its “outperform” rating reaffirmed by Raymond James Financial, Inc..
• 2/16/2026 – Compass Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/13/2026 – Compass Therapeutics is now covered by Craig Hallum. They set a “buy” rating and a $15.00 price target on the stock.
• 2/8/2026 – Compass Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/4/2026 – Compass Therapeutics was given a new $13.00 price target by Canaccord Genuity Group Inc..
• 1/31/2026 – Compass Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.